Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  1. Bidard, F.-C.
  2. Kaklamani, V.G.
  3. Neven, P.
  4. Streich, G.
  5. Montero, A.J.
  6. Forget, F.
  7. Mouret-Reynier, M.-A.
  8. Sohn, J.H.
  9. Taylor, D.
  10. Harnden, K.K.
  11. Khong, H.
  12. Kocsis, J.
  13. Dalenc, F.
  14. Dillon, P.M.
  15. Babu, S.
  16. Waters, S.
  17. Deleu, I.
  18. García Sáenz, J.A.
  19. Bria, E.
  20. Cazzaniga, M.
  21. Lu, J.
  22. Aftimos, P.
  23. Cortés, J.
  24. Liu, S.
  25. Tonini, G.
  26. Laurent, D.
  27. Habboubi, N.
  28. Conlan, M.G.
  29. Bardia, A.
  30. Montrer des auteurs +
Revue:
Journal of Clinical Oncology

ISSN: 1527-7755,  0732-183X

Année de publication: 2022

Volumen: 32

Type: Article

DOI: 10.1200/JCO.22.00338 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus